All In Biotech

Drug Trial Radar · NCT05939414

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease Recurrence in Adult Male Patients With Prostate-specific Membrane Antigen (PSMA) Positive Oligometastatic Prostate Cancer (OMPC)

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

450

Planned (sponsor's estimate)

Start

Mar 12, 2024

Primary completion

Apr 25, 2028

Study completion Oct 3, 2031

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jul 11, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. The data generated from this study will provide evidence for the treatment of AAA617 in early-stage prostate cancer patients to control recurrent tumor from progressing to fatal metastatic disease while preserving quality of life by delaying treatment with androgen deprivation therapy (ADT).

Conditions

  • Oligometastatic Prostate Cancer (OMPC)

Interventions

  • AAA617Drug

    Radiopharmaceutical solution for infusion/injection

  • piflufolastat (18F)Drug

    Provided as ready-to-use radiopharmaceutical

  • gallium (68Ga) gozetotide (25μg)Drug

    Provided as PSMA-11 Kit for radiopharmaceutical preparation of gallium (68Ga) gozetotide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Blinded Independent Review Committee (BIRC) assessed Metastasis Free Survival (MFS)Time frame: From date of randomization until first evidence of radiographically detectable bone or soft tissue distant metastasis or death due to any cause, whichever occurs first, assessed up to approximately 30 months

Locations

144 sites in 27 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group

    Fayetteville, Arkansas · Recruiting

  • VA Greater LA Healthcare System

    Los Angeles, California · Recruiting

  • VA Palo Alto Health Care System

    Palo Alto, California · Recruiting

  • Stanford University

    Palo Alto, California · Recruiting

  • UCSF

    San Francisco, California · Recruiting

  • Rocky Mountain Cancer Centers

    Denver, Colorado · Recruiting

  • Cancer Specialists of North Florida

    Jacksonville, Florida · Recruiting

  • Woodlands Medical Specialists

    Pensacola, Florida · Recruiting

  • Piedmont Healthcare

    Atlanta, Georgia · Recruiting

  • University of Chicago

    Chicago, Illinois · Recruiting

  • The Cancer Institute of Alexian Brothers

    Elk Grove, Illinois · Recruiting

  • Unity Point Clinic

    Des Moines, Iowa · Recruiting

  • University of Kansas Hospital

    Kansas City, Kansas · Recruiting

  • Mary Bird Perkins Cancer Center

    Baton Rouge, Louisiana · Recruiting

  • East Jefferson Hospital

    Metairie, Louisiana · Recruiting

  • University of Maryland Medical Ctr

    Baltimore, Maryland · Recruiting

  • Johns Hopkins Kimmel Com Cancer Ctr

    Baltimore, Maryland · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Beth Israel Deaconess Med Ctr

    Boston, Massachusetts · Recruiting

  • BAMF Health

    Grand Rapids, Michigan · Withdrawn

  • Profound Research LLC

    Royal Oak, Michigan · Withdrawn

  • William Beaumont Hospital

    Royal Oak, Michigan · Recruiting

  • Mayo Clinic Rochester

    Rochester, Minnesota · Recruiting

  • St Louis University

    St Louis, Missouri · Recruiting

  • VA St Louis Health Care System

    St Louis, Missouri · Withdrawn

  • Wash U School of Medicine

    St Louis, Missouri · Recruiting

  • The Urology Center PC DBA UroHealth Partners

    Omaha, Nebraska · Recruiting

  • Memorial Sloan Kettering Cancer Ctr

    New York, New York · Recruiting

  • Associated Med Professionals of NY

    Syracuse, New York · Recruiting

  • Montefiore Hospital

    The Bronx, New York · Recruiting

  • East Carolina University

    Greenville, North Carolina · Recruiting

  • Dayton Physicians

    Kettering, Ohio · Recruiting

  • Oregon Urology Institute

    Springfield, Oregon · Recruiting

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • Univ of Texas Southwest Med Center

    Dallas, Texas · Recruiting

  • Rio Grande Urology

    El Paso, Texas · Recruiting

  • Virginia Oncology Associates

    Norfolk, Virginia · Recruiting

  • Blue Ridge Cancer Center

    Wytheville, Virginia · Recruiting

  • Novartis Investigative Site

    Caba, Argentina · Recruiting

Showing 40 of 144 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.